Search research articles
Contact Us
Filters
Showing results (11-20 of 64) with videos related to
Page
of 7
Sort By:
Cell Transplantation
|
August 20, 2010
Lack of evidence for recipient precursor cells replenishing β-cells in transplanted islets
Yoshiyuki Hamamoto, Tomoyuki Akashi, Akari Inada, et al.
Diabetes Research and Clinical Practice
|
December 9, 2008
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes
Hiroki Ikeda, Yoshiyuki Hamamoto, Sachiko Honjo, et al.
Expert Opinion on Drug Safety
|
July 26, 2017
Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation
Daisuke Yabe, Yoshiyuki Hamamoto, Yusuke Seino, et al.
Journal of Diabetes
|
March 2, 2018
Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial
Kanta Fujimoto, Yui Shibayama, Eriko Yamaguchi, et al.
Journal of Physical Therapy Science
|
March 13, 2019
Evaluation of skeletal muscle mass indices, assessed by bioelectrical impedance, as indicators of insulin resistance in patients with type 2 diabetes
Yoshikazu Hirasawa, Ryosuke Matsuki, Toshihiko Ebisu, et al.
Endocrinology
|
December 26, 2001
Prior exposure to high glucose augments depolarization-induced insulin release by mitigating the decline of ATP level in rat islets
Shimpei Fujimoto, Eri Mukai, Yoshiyuki Hamamoto, et al.
Clinical Drug Investigation
|
June 19, 2017
Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study
Yoshiyuki Hamamoto, Sachiko Honjo, Kanta Fujimoto, et al.
Journal of Diabetes Investigation
|
January 20, 2026
Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes
Yasuhiro Omori, Ryota Usui, Yuji Yamazaki, et al.
The Lancet. Diabetes & Endocrinology
|
April 26, 2020
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto, et al.
Endocrine
|
October 21, 2010
Japanese cases of acute onset diabetic ketosis without acidosis in the absence of glutamic acid decarboxylase autoantibody
Yorihiro Iwasaki, Yoshiyuki Hamamoto, Yukiko Kawasaki, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 64) with videos related to
Sort By:
Page
of 7
Cell Transplantation
|
August 20, 2010
Lack of evidence for recipient precursor cells replenishing β-cells in transplanted islets
Yoshiyuki Hamamoto, Tomoyuki Akashi, Akari Inada, et al.
Diabetes Research and Clinical Practice
|
December 9, 2008
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes
Hiroki Ikeda, Yoshiyuki Hamamoto, Sachiko Honjo, et al.
Expert Opinion on Drug Safety
|
July 26, 2017
Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation
Daisuke Yabe, Yoshiyuki Hamamoto, Yusuke Seino, et al.
Journal of Diabetes
|
March 2, 2018
Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial
Kanta Fujimoto, Yui Shibayama, Eriko Yamaguchi, et al.
Journal of Physical Therapy Science
|
March 13, 2019
Evaluation of skeletal muscle mass indices, assessed by bioelectrical impedance, as indicators of insulin resistance in patients with type 2 diabetes
Yoshikazu Hirasawa, Ryosuke Matsuki, Toshihiko Ebisu, et al.
Endocrinology
|
December 26, 2001
Prior exposure to high glucose augments depolarization-induced insulin release by mitigating the decline of ATP level in rat islets
Shimpei Fujimoto, Eri Mukai, Yoshiyuki Hamamoto, et al.
Clinical Drug Investigation
|
June 19, 2017
Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study
Yoshiyuki Hamamoto, Sachiko Honjo, Kanta Fujimoto, et al.
Journal of Diabetes Investigation
|
January 20, 2026
Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes
Yasuhiro Omori, Ryota Usui, Yuji Yamazaki, et al.
The Lancet. Diabetes & Endocrinology
|
April 26, 2020
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto, et al.
Endocrine
|
October 21, 2010
Japanese cases of acute onset diabetic ketosis without acidosis in the absence of glutamic acid decarboxylase autoantibody
Yorihiro Iwasaki, Yoshiyuki Hamamoto, Yukiko Kawasaki, et al.
Page
of 7